Emergent BioSolutions (EBS) Earnings Analysis
Emergent BioSolutions (EBS) has no confirmed upcoming earnings date. Last quarter (2026-04-30) it beat with EPS 0.21 USD vs -0.25 USD est (+184%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E -44.59.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does EBS next report earnings?
No confirmed upcoming earnings date is currently scheduled for EBS. This page updates as the calendar is published.
EBS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | 0.21 USD | -0.25 USD | +184% | Beat |
| 2026-02-26 | -0.43 USD | 0.11 USD | -490.9% | Miss |
| 2025-03-03 | 0.05 USD | -0.35 USD | +114.3% | Beat |
Beat rate: 2/3 (67%) over reported quarters with consensus data.
EBS valuation and analyst view
| Trailing P/E | -44.59 |
|---|---|
| Trailing EPS | -0.1657 USD |
| Price / book | 0.75 |
| Dividend yield | 0.00% |
| Market cap | 0.39B |
| Analyst consensus | Buy (11 buy / 3 hold / 1 sell) |
| Avg price target | 12 USD |
Related research pages
Frequently asked questions
When is Emergent BioSolutions (EBS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for EBS. This page updates as the calendar is published.
Did EBS beat earnings last quarter?
In its 2026-04-30 report, EBS posted EPS of 0.21 USD versus a -0.25 USD estimate — a beat of 184%.
What is EBS's earnings track record?
Over the last 3 reported quarters with consensus data, EBS beat estimates 2 times (67%).
What is EBS's current P/E ratio and EPS?
EBS trades at a trailing P/E of -44.59 on trailing EPS of -0.16570327552986513 USD.
What do analysts rate EBS?
Analyst consensus is "Buy" across 15 ratings (0 strong buy, 11 buy, 3 hold, 1 sell, 0 strong sell). Average 12-month price target: 12 USD.